Aseem Anand

1.9k total citations
33 papers, 865 citations indexed

About

Aseem Anand is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Aseem Anand has authored 33 papers receiving a total of 865 indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 22 papers in Radiology, Nuclear Medicine and Imaging and 13 papers in Oncology. Recurrent topics in Aseem Anand's work include Prostate Cancer Treatment and Research (31 papers), Radiopharmaceutical Chemistry and Applications (18 papers) and Bone health and treatments (8 papers). Aseem Anand is often cited by papers focused on Prostate Cancer Treatment and Research (31 papers), Radiopharmaceutical Chemistry and Applications (18 papers) and Bone health and treatments (8 papers). Aseem Anand collaborates with scholars based in United States, Sweden and Germany. Aseem Anand's co-authors include Howard I. Scher, Martin Fleisher, Daniel C. Danila, Glenn Heller, Anders Bjartell, Michael J. Morris, Lars Edenbrandt, Clifford C. Sung, Hans Lilja and Arturo Molina and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and European Urology.

In The Last Decade

Aseem Anand

32 papers receiving 857 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aseem Anand United States 17 668 383 345 313 135 33 865
Jessica Louw United States 9 692 1.0× 479 1.3× 114 0.3× 532 1.7× 249 1.8× 30 988
Ines Figueiredo United Kingdom 11 356 0.5× 237 0.6× 93 0.3× 232 0.7× 185 1.4× 26 576
Ryan D. Stephenson United States 9 370 0.6× 281 0.7× 185 0.5× 98 0.3× 103 0.8× 18 539
Spyridon Sideris Belgium 11 379 0.6× 158 0.4× 189 0.5× 154 0.5× 65 0.5× 27 504
Hielke J. Meulenbeld Netherlands 11 316 0.5× 283 0.7× 86 0.2× 176 0.6× 149 1.1× 17 577
D. Ilegbodu United States 12 181 0.3× 574 1.5× 155 0.4× 162 0.5× 105 0.8× 30 711
Alexis K. Smith United States 7 341 0.5× 145 0.4× 122 0.4× 118 0.4× 66 0.5× 10 513
Zoe Wainer Australia 10 826 1.2× 386 1.0× 191 0.6× 164 0.5× 150 1.1× 12 990
Merdol Ibrahim United Kingdom 15 146 0.2× 469 1.2× 262 0.8× 275 0.9× 254 1.9× 19 735
Martin Heubner Germany 18 121 0.2× 283 0.7× 238 0.7× 166 0.5× 198 1.5× 47 869

Countries citing papers authored by Aseem Anand

Since Specialization
Citations

This map shows the geographic impact of Aseem Anand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aseem Anand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aseem Anand more than expected).

Fields of papers citing papers by Aseem Anand

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aseem Anand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aseem Anand. The network helps show where Aseem Anand may publish in the future.

Co-authorship network of co-authors of Aseem Anand

This figure shows the co-authorship network connecting the top 25 collaborators of Aseem Anand. A scholar is included among the top collaborators of Aseem Anand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aseem Anand. Aseem Anand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Probst, Stephan, et al.. (2022). Interval Changes in PSMA PET/CT During Radium-223 Therapy for Metastatic Bone Disease from Castration-Resistant Prostate Cancer. Nuclear Medicine and Molecular Imaging. 56(4). 188–195. 4 indexed citations
2.
Anand, Aseem, Glenn Heller, Daniel C. Danila, et al.. (2022). Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer. 20(3). 270–277. 3 indexed citations
3.
4.
Nickols, Nicholas G., et al.. (2021). aPROMISE: A Novel Automated PROMISE Platform to Standardize Evaluation of Tumor Burden in 18F-DCFPyL Images of Veterans with Prostate Cancer. Journal of Nuclear Medicine. 63(2). 233–239. 44 indexed citations
5.
Nickols, Nicholas G., Matthew B. Rettig, Stephan Probst, et al.. (2021). Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting. European Journal of Nuclear Medicine and Molecular Imaging. 49(3). 1041–1051. 36 indexed citations
6.
Sjöstrand, Karl, et al.. (2018). Automated detection and quantification of prostatic PSMA uptake in SPECT/CT using a deep learning algorithm for segmentation of pelvic anatomy. 59. 30–30. 2 indexed citations
7.
Armstrong, Andrew J., Lars Edenbrandt, Eva Bondesson, et al.. (2017). Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 35(15_suppl). 5006–5006. 4 indexed citations
8.
9.
Anand, Aseem, Michael J. Morris, Reza Kaboteh, et al.. (2016). A Preanalytic Validation Study of Automated Bone Scan Index: Effect on Accuracy and Reproducibility Due to the Procedural Variabilities in Bone Scan Image Acquisition. Journal of Nuclear Medicine. 57(12). 1865–1871. 22 indexed citations
10.
Anand, Aseem, Michael J. Morris, Steven M. Larson, et al.. (2016). Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Research. 6(1). 23–23. 34 indexed citations
11.
12.
Alva, Ajjai, Luke T. Nordquist, Stephanie Daignault, et al.. (2016). Clinical Correlates of Benefit From Radium‐223 Therapy in Metastatic Castration Resistant Prostate Cancer. The Prostate. 77(5). 479–488. 40 indexed citations
13.
Anand, Aseem, Michael J. Morris, Reza Kaboteh, et al.. (2015). Analytic Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer. Journal of Nuclear Medicine. 57(1). 41–45. 37 indexed citations
14.
Danila, Daniel C., Aseem Anand, Nikolaus Schultz, et al.. (2013). Analytic and Clinical Validation of a Prostate Cancer–Enhanced Messenger RNA Detection Assay in Whole Blood as a Prognostic Biomarker for Survival. European Urology. 65(6). 1191–1197. 60 indexed citations
15.
16.
Danila, Daniel C., Aseem Anand, Clifford C. Sung, et al.. (2011). TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate. European Urology. 60(5). 897–904. 152 indexed citations
17.
Anand, Aseem, Howard I. Scher, Tomasz M. Beer, et al.. (2010). Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100.. Journal of Clinical Oncology. 28(15_suppl). 4546–4546. 4 indexed citations
18.
Danila, Daniel C., Aseem Anand, Clifford C. Sung, et al.. (2010). Molecular profiling of circulating tumor cells (CTC) in patients with castrate metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy.. Journal of Clinical Oncology. 28(15_suppl). 4635–4635. 2 indexed citations
19.
Scher, Howard I., Tomasz M. Beer, Celestia S. Higano, et al.. (2009). Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 27(15_suppl). 5011–5011. 33 indexed citations
20.
Danila, Daniel C., Dana E. Rathkopf, M. J. Morris, et al.. (2008). Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 5019–5019. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jessica Louw Breakdown of academic impact, for papers by Ines Figueiredo Breakdown of academic impact, for papers by Ryan D. Stephenson Breakdown of academic impact, for papers by Spyridon Sideris Breakdown of academic impact, for papers by Hielke J. Meulenbeld Breakdown of academic impact, for papers by D. Ilegbodu Breakdown of academic impact, for papers by Alexis K. Smith Breakdown of academic impact, for papers by Zoe Wainer Breakdown of academic impact, for papers by Merdol Ibrahim Breakdown of academic impact, for papers by Martin Heubner
Rankless by CCL
2026